Founded in 1886 in Basel, Switzerland, by Alfred Kern and Edouard Sandoz, Sandoz Group AG has developed into the global leader in generic and biosimilar medicines, with a heritage that combines long-standing pharmaceutical expertise with a clear focus on expanding access to treatment. Following its spin-off from Novartis and return as an independent publicly listed company in October 2023, Sandoz is headquartered in Basel and today supplies around 1,300 products to more than 100 countries, reaching over 1 billion patients each year. In 2025, the company reported net sales of USD 11.1 billion and employed more than 23,000 people worldwide, reflecting its scale and strategic importance in global healthcare.
Updated 2026-03-19